DNAP VOR KURSSPRUNG!!!!!!!!!!!!! - 500 Beiträge pro Seite

[BIOM]

NASDAQ OTC: DNAP



Homepage: http://www.dnaprint.com







Latest Press Releases....



DNAPrint™ genomics, Inc. Agrees to Acquire Majority Ownership in German Pharmaceutical Company Biofrontera AG; Secures $35 Million Equity Commitment from Dutchess Private Equities Fund, L.P.


DNAPrintTM genomics, Inc. is a genomics science company focused on the sale of unique proprietary genetic testing products and services. The Company’s core patented and proprietary technologies for efficiently targeting single nucleotide polymorphisms (“SNPs”) enable us to provide novel predictive genetic tests at a significant cost advantage over our competitors.



We have identified and patented the maps of certain SNPs that we believe have broad commercial applications. These commercially valuable SNPs are called Ancestry Informative Markers (“AIMs”) and are mapped by us using our proprietary Mapping by Admixture Linkage Disequilibrium (“MALD”) method. With MALD, we leverage known statistical data about population structure to substantially reduce the number of SNPs analyzed and therefore more cost effectively identify genes responsible for certain traits. Our patented AIMs are integral to our strategy of offering DNA tests that provide valuable predictive results, including a person’s physical characteristics, Biogeographical Ancestry (“BGA”), and predisposition to respond to certain pharmaceutical drugs.

We are currently focusing our efforts in four distinct markets:

Pharmacogenomics Market - The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition.

Forensics DNA Testing Market - Testing DNA to create a physical profile of crime suspects is a new market based on evolving technologies. Common hereditary traits such as skin pigmentation, eye color, hair color, earlobe attachment and height can be predicted through analysis of DNA sequences. DNAPrintTM believes it is the first company to use DNA evidence to successfully profile a crime suspect by predicting that suspect’s continental origin.

Consumer DNA Products Market - There is an established market of consumers who recreationally research their genealogy and ancestral origin. Additionally, there is a market for paternity tests and other tests related to lineage. DNAPrintTM serves both of these consumer market segments through direct sales and independent distributors.

Contract Service Outsourcing Market - DNAPrintTM provides universities and drug discovery companies with genotyping services. The service provides our clients with the ability to screen efficiently and effectively for genes that may be responsible for certain human traits and/or disease states.

We see exciting growth opportunity in these markets to introduce and sell our novel products and services. DNAPrintTM genomics, Inc. putting the puzzle together.

[BIOM]

Code of Business Conduct and Ethics



Overview



The following principles support and guide our leadership in establishing the strategic direction of DNAPrint genomics, Inc. Our directors, officers and employees are expected to conduct their business in accordance with these ethical principles. We must do more than be compliant with laws, regulations and policies; we must work according to our ethical principles and endeavor to conduct ourselves in a manner beyond reproach. Any employee who ignores or violates any of DNAPrint`s ethical standards, or who penalizes a subordinate for trying to follow these ethical standards, will be subject to corrective action, including immediate dismissal. Nevertheless, it is not the threat of discipline that should govern your actions. DNAPrint`s reputation is based on the personal integrity of each of its employees and those with whom we do business. A dedicated commitment to ethical behavior is the right thing to do, is good business, and is the surest way for DNAPrint to become and remain a business leader, employer of choice, and good corporate citizen.



In the final analysis, you are the guardian of DNAPrint`s ethics. While there are no universal rules, when in doubt ask yourself:

Would I be proud to explain my actions to my family or fellow employees – or to the millions of people who see the nightly news or read the newspaper?

If not, don`t do it!



Ethics



DNAPrint, and each of its directors, officers and employees must conduct their affairs with uncompromising honesty and integrity. Business ethics are no different than personal ethics. The same high standard applies to both. As a DNAPrint employee, you are required to adhere to the highest standard regardless of local custom.



DNAPrint personnel are expected to be honest and ethical in dealing with each other, with customers, vendors and all other third parties. Doing the right thing means doing it right every time.



You must also respect the rights of your fellow employees and third parties. Your actions must be free from discrimination, libel, slander or harassment. Each person must be treated with dignity and respect and accorded equal opportunity, regardless of age, race, sex, sexual preference, color, creed, religion, national origin, marital status, veteran`s status, handicap or disability.



Misconduct cannot be excused because it was directed or requested by another. In this regard, you are expected to alert management whenever an illegal, dishonest or unethical act is discovered or suspected. You will never be penalized for reporting your discoveries or suspicions.



DNAPrint conducts its affairs consistent with the applicable laws and regulations of the United States and those other countries where it does business. As a DNAPrint employee, you are expected to comply with all such applicable laws and regulations. Business practices, customs and laws differ from country to country. When conflicts arise between DNAPrint`s ethical practices, and the practices, customs, and the laws of a country, DNAPrint seeks to resolve them consistent with its ethical beliefs. If the conflict cannot be resolved consistent with its ethical beliefs, DNAPrint will not proceed with the proposed action giving rise to the conflict. These ethical standards reflect who we are and are the standards by which we choose to be judged.



The following statements concern frequently raised ethical concerns. A violation of the standards contained in this Code of Business Conduct and Ethics will result in corrective action, including possible dismissal.



Conflicts of Interest



You must avoid any personal activity, investment or association which could appear to interfere with good judgment concerning DNAPrint`s best interests. You may not exploit your position or relationship with DNAPrint for personal gain. You should avoid even the appearance of such a conflict. Therefore, if you are related in any way to a vendor, customer or other provider, you should not be the one to decide whether DNAPrint will to do business with that person.



As other examples, there is a likely conflict of interest if you:

cause DNAPrint to engage in business transactions with you or your relatives or friends or entities controlled by you or them;

use nonpublic DNAPrint, customer or vendor information for personal gain by you, relatives or friends (including securities transactions based on such information);

have more than a modest financial interest in DNAPrint`s vendors, customers or competitors;

receive a loan, or guarantee of obligations, from DNAPrint or a third party as a result of your position at DNAPrint; or

compete, or prepare to compete, with DNAPrint while still employed by DNAPrint.

There are other situations in which a conflict of interest may arise. If you have concerns about any situation, follow the steps outlined in the section on "Reporting Violations."



To ensure that material transactions and relationships involving a potential conflict of interest for any officer or director are in the best interests of DNAPrint, the Board must approve in advance all transactions and relationships in which an officer or a director, or any member of any such person`s family, may have a personal interest or other potential conflict of interest. No director, officer or employee may, on behalf of DNAPrint, authorize or approve any transaction or relationship, or enter into any agreement, in which any director, officer or any member of his or her immediate family, may have a personal interest without such Board approval.



Gifts, Bribes and Kickbacks



Other than for modest gifts given or received in the normal course of business (including travel or entertainment), neither you nor your relatives may give gifts to, or receive gifts from, DNAPrint`s customers and vendors. Other gifts may be given or accepted only with prior approval of your senior management. In no event should you put DNAPrint or yourself in a position that would be embarrassing if the gift were made public.



Dealing with government employees is often different than dealing with private persons. Many governmental bodies strictly prohibit the receipt of any gratuities by their employees, including meals and entertainment. You must be aware of and strictly follow these prohibitions.



Any person associated with DNAPrint who pays or receives bribes or kickbacks will be immediately terminated and reported, as warranted, to the appropriate authorities. A kickback or bribe includes any item intended to improperly obtain favorable treatment.



Improper Use or Theft of DNAPrint Property



Every employee must safeguard DNAPrint property from loss or theft, and may not take such property for personal use. DNAPrint property includes physical resources and property, as well as its proprietary and confidential information, software, computers, office equipment, and supplies. You must appropriately secure all DNAPrint property within your control to prevent its unauthorized use.



Our offices, equipment, supplies and other resources may not be used for activities which are not related to your employment with DNAPrint, except for any activities that have been approved in writing in advance by us, or for personal usage that is minor in amount and reasonable.



Use of DNAPrint`s electronic communications systems must conform with DNAPrint`s corporate philosophy and policies. In addition, you should not use DNAPrint`s computer systems to access or post material that: is pornographic, obscene, sexually related, profane or otherwise offensive; is intimidating or hostile; or violates DNAPrint policies or any laws or regulations. Employees may make limited non-business use of DNAPrint`s electronic communications systems, provided that such use: (i) is occasional; (ii) does not interfere with the employee`s professional responsibilities; (iii) does not diminish productivity; and (iv) does not violate this policy or any other DNAPrint policy.



Maintaining Accurate and Complete Company Records; Covering Up Mistakes



DNAPrint is required under U.S. federal securities laws and generally accepted accounting principles to keep books, records and accounts that accurately reflect all transactions, to provide an adequate system of internal accounting and controls. DNAPrint also is required to provide full, fair, accurate, timely and understandable disclosure in reports and documents that it files with, or submits to, the SEC and in all its other public communications. DNAPrint expects all personnel to ensure that those portions of our books, records and accounts for which they have responsibility are valid, complete, accurate and supported by appropriate documentation in verifiable form. Similarly, DNAPrint expects all personnel to ensure that all reports and documents filed with the SEC and all other public communications for which they are responsible provide full, fair, accurate and understandable disclosure and that the same are filed on a timely basis.



All employees who exercise supervisory duties over DNAPrint assets or records are expected to establish and implement appropriate internal controls over all areas of their responsibility. This will help ensure the safeguarding of DNAPrint`s assets and the accuracy of our financial records and reports. DNAPrint has adopted various types of internal controls and procedures as required to meet internal needs and applicable laws and regulations. The Company expects all personnel to follow these controls and procedures to assure the complete and accurate recording of all transactions.



Any accounting entries or adjustments that materially depart from generally accepted accounting principles must be approved by our Board of Directors` Audit Committee and reported to our independent auditors. No one may interfere with or seek to improperly influence (directly or indirectly) the review or auditing of our financial records by DNAPrint`s independent auditors.



If a director, officer or employee becomes aware of any questionable transaction or accounting practice concerning DNAPrint or its assets, or material off-balance-sheet transactions, arrangements and obligations, contingent or otherwise, and other DNAPrint relationships with unconsolidated entities or other persons that may have material current or future effects on the Company`s financial condition or results of operations, DNAPrint expects the matter to be reported immediately to DNAPrint`s legal counsel or to a member of our Audit Committee.



Mistakes should never be covered up, but should be immediately fully disclosed and corrected. Falsification of any DNAPrint, customer or third party record is prohibited.



Protection of DNAPrint, Client or Vendor Information



No one may use or reveal to others DNAPrint, customer or vendor confidential or proprietary information. Additionally, all personnel must take appropriate steps – including securing documents, limiting access to computers and electronic media, and proper disposal methods – to prevent unauthorized access to such information. Proprietary and/or confidential information, among other things, includes: business methods, pricing and marketing data, strategy, computer code, forms, experimental research, and information about, or received from, DNAPrint`s current, former and prospective customers, vendors and employees.



Competitive Information, Defamation and Misrepresentation



No one may accept, use or disclose to others the confidential information of DNAPrint`s competitors. When obtaining competitive information, personnel must not violate DNAPrint`s competitors` rights. Particular care must be taken when dealing with competitors` customers, ex-customers and ex-employees. Never ask for confidential or proprietary information. Never ask a person to violate a non-compete or non-disclosure agreement. Aggressive sales and marketing should not include misstatements, innuendo or rumors about DNAPrint`s competition or their products and financial condition. Do not make insupportable promises concerning DNAPrint`s products.



Use of DNAPrint and Third Party Software



DNAPrint and third party software may be distributed and disclosed only to employees authorized to use it, and to customers in accordance with terms of a DNAPrint agreement. DNAPrint and third party software may not be copied without specific authorization and may only be used to perform assigned responsibilities.



Fair Competition and Antitrust Laws



DNAPrint must comply with all applicable fair competition and antitrust laws. These laws attempt to ensure that businesses compete fairly and honestly and prohibit conduct seeking to reduce or restrain competition. If you are uncertain whether a contemplated action raises unfair competition or antitrust issues, the Company`s legal counsel can assist you.



Securities Trading



It is illegal to buy or sell securities using material information not available to the public. Persons who give such undisclosed "inside" information to others may be as liable as persons who trade securities while possessing such information. Securities laws may be violated if a director, officer or employee, or any of their relatives or friends trade in securities of DNAPrint, or any of its customers or vendors, while possessing "inside" information.



Political Contributions



No company funds may be given directly to political candidates. Directors, officers and employees may engage in political activity with their own resources on their own time.



Retention of Business Records



DNAPrint business records must be maintained for the periods specified in DNAPrint`s record retention policies. Records may be destroyed only at the expiration of the pertinent period. In no case may documents involved in a pending or threatened litigation, government inquiry or under subpoena or other information request, be discarded or destroyed, regardless of the periods specified in the applicable policy. In addition, no one should ever destroy, alter, or conceal, with an improper purpose, any record or otherwise impede any official proceeding, either personally, in conjunction with, or by attempting to influence, another person.



A Healthy and Safe Workplace; No Harassment



When DNAPrint protects the health and safety of its employees, the community, and the environment, it demonstrates respect and contributes to a positive work environment. Without respect for health, safety, and the environment, DNAPrint would put its personnel, customers and the public at risk.



DNAPrint is committed to protecting the health and safety of its employees, the public, our customers, suppliers, and visitors. DNAPrint`s policy is to maintain a secure workplace where all employees are attentive to hazard prevention and the avoidance of accidents and injuries. Posted safety regulations, statistics, and warnings are guides to help everyone stay out of harm`s way – observed accidents, injuries, or hazards should be immediately reported to company leadership.



DNAPrint does not tolerate harassment of our employees, nor do we tolerate any retaliation against a person reporting harassment.



Waivers



The Code of Business Conduct and Ethics applies to all DNAPrint officers and employees and the members of its Board of Directors. There will be no waiver of any part of the Code for any officer or director except by a vote of the Board, which will ascertain whether a waiver is appropriate and ensure that the waiver is accompanied by appropriate controls designed to protect DNAPrint. Waivers of any part of the Code for any other employee may be granted by the Chairman, the Chief Executive Officer or the Chief Financial Officer.



In the event that any waiver is granted for any officer or director, the waiver, and the reasons for it, will be posted on the DNAPrint website, thereby allowing DNAPrint`s shareholders to evaluate the merits of the particular waiver.



Reporting Violations



Each person`s conduct can reinforce an ethical atmosphere and positively influence the conduct of one`s fellow employees. If an employee is powerless to stop suspected misconduct or discovers it after it has occurred, he or she must report it to management.



All DNAPrint directors, officers and employees are required to report, or cause to be reported, information known to them, and assist in any investigation by any regulatory or law enforcement agency, elected officials or others responsible for such matters, concerning the following:

violation of any federal. state or local laws, regulations or rules by any DNAPrint director, officer, employee or agent in connection with DNAPrint or its business;

questionable accounting, internal controls and auditing matters concerning DNAPrint;

the conduct of any DNAPrint director, officer, employee or agent in connection with DNAPrint or its business that is not honest and ethical;

conflicts of interest which have not been reported as required by this Code;

disclosures in DNAPrint`s SEC reports and other public disclosures that are not full, fair, accurate, timely and understandable;

violations of this Code of Ethics.

No Retaliation; Confidentiality



Part of your job at DNAPrint is "to do the right thing." DNAPrint will not take any personnel or other action against someone who reports or otherwise tries to stop suspected wrongdoing.



More specifically, DNAPrint will not – and no officer or employee may – retaliate against anyone who provides, or causes to be provided, information, or who files, causes to be filed, testifies, participates in, or otherwise assists in a proceeding regarding any matter covered in the preceding section entitled "Reporting Violations." The anonymity of a reporting person and the confidentiality of the information that is reported will be maintained if such person so requests; however, the identity of the person and the information reported may be disclosed to the extent necessary to conduct an effective investigation. Any person who believes that he or she has been subject to retaliation by the Company, or any officer or employee, as a result of a report, testimony, assistance in a proceeding or otherwise, should report such retaliation to a member of the Board`s Audit Committee. The Audit Committee will conduct an appropriate investigation and take such action as it determines necessary to effect compliance with this Code and applicable law

[BIOM]

Pharmacogenomics


Over the next 10 years, the worldwide pharmaceutical market is expected to grow from $320 billion to $2 trillion, driven primarily by the flood of new drug targets identified through genomics and through the co-development of drugs and accompanying genomics response tests. The primary objective of DNAPrintTM‘s near term research and development efforts in pharmacogenomics will be to expand our library of predictive drug response tests to include multiple therapeutic areas which include commonly used FDA approved drug therapies.



We currently have two pharmacogenomic tests in development:

OVANOMETM- DNAPrintTM scientists are working on a genomic-based diagnostic tool to match ovarian cancer patients with the most suitable form and dose of chemotherapy. Currently, cancer patients are treated with anti-cancer drugs whose efficacy is known in terms of population averages. In reality, individual cancer patients exhibit unpredictable and unique responses to virtually all commonly used chemotherapeutic compounds. Individual genetic differences have long been suspected to play a role in this variable drug response. For cancer patients, decisions about treatment regimes are often fateful, and second chances at treatment are sometimes not successful. A better understanding of the relationship between genes and drug response can replace the current trial and error process of chemotherapy treatment and guide physicians and patients toward the optimal treatments at the outset of therapy. In early March 2000, DNAPrintTM announced success with this project at the Society of Gynecological Oncologists meeting in Miami, and at the BIO IT World Expo in Boston.

Our scientists have identified several Single Nucleotide Polymorphism (“SNP”) markers whose haploid alleles are predictive for non-response to the Taxol and Carboplatin drug combination, a drug combination manufactured by Bristol-Myers Squibb for the treatment of ovarian cancer.



Once funding sufficient to screen 250 patients at $1,000 per patient is received, OVANOMETM will be tested in clinical trials for monitoring and reporting on the use of Taxol and Carboplatin. Our Chief Medical Officer, Hector J. Gomez, MD, PhD will lead the clinical development process.



FDA rules regarding pharmacogenomics testing are still evolving and we are seeking additional guidance from the FDA on this issue. Until OVANOMETM is FDA approved or deemed to not require FDA approval, we plan on generating revenues through physician guided Investigative New Drug studies.

STATINOMETM- This test is currently being developed for the cardiac drug market. STATINOMETM is being developed in conjunction with a group of Jacksonville, Florida physicians to classify patients as adverse responders or good responders to a class of drugs known as “statins”. Statins are drugs used to treat patients who are at increased risk of heart disease. Approximately 50% of the U.S. population is at risk of heart disease as a result of high cholesterol. While statins have been demonstrated to be effective at cholesterol reduction, decreasing incidence of heart disease by 10.3% from 1990 to 1994, adverse reactions can include liver damage and kidney failure. Approximately 2-5% of patients must discontinue statin use due to these adverse side effects. Once perfected, we believe STATINOMETM will be able to dramatically improve the rewards associated with taking statins by obviating the risks associated with adverse response. STATINOMETM is projected to enter clinical studies for FDA approval by late 2004 or early 2005.

[BIOM]

aktueller Kurs:




weitere Kursinformationen unter:

http://www.otcbb.com/asp/quote_module.asp?symbol=DNAP

Marktkapitalisierung unter 9 Mio $

[BIOM]

Strong Buy!!!!!!!!

[Michiko]

Frage:

Was steht jetzt hier, was nicht schon längst im "anderen" Thread dargestellt worden ist?

Michi

[BIOM]

@Michiko, das Geld mit DNAP zu verdienen ist!

[Michiko]

Was denkst Du, warum ich inzwischen über eine Million shares halte!

[BIOM]

@michiko, jedenfalls glaube ich das DNAP bald auf 0,02$ steht

[Michiko]

@BIOM

2 Cent interessieren mich relativ wenig. Ich rechne mit weit höheren Kursen. Das aber nur auf (sehr) lange Sicht.

Aber bei DNAP kann ich warten.

[BIOM]

heute gehts jedenfalls auf 0,015

[hvs1]

BIom,

noch nicht.Ich habe eine Order 1M zu 0,0115 drin.

hvs1

[Michiko]

hvs1

gehst ja auch mächtig rein!

Ich drück Dir die Daumen. Bin selber cashmäßig leider auf Null.

[hvs1]

Michi,

meine 7400 Stck ICGE haben mich wieder ein wenig nach
vorn gebracht.
Sollte die Order durchgehen,verkauf ich 1400 Stck ICGE.

Mein Ziel sind 2M DNAP.

Gruß hvs1

[McFlying]

ruhiger Handel heute

[McFlying]

Police hail swift DNA technology
By JONATHAN D. SILVER
Pittsburgh Post-Gazette
December 19, 2004

- DNA technology - and its use in crime fighting - has undergone an amazing transformation in recent years.

Samples of a human being`s genetic material that were once considered too small, too old or too contaminated to be used in a case are now considered viable. Large DNA databases of criminals have been compiled and are used regularly by law enforcement. And DNA is being mined for ever more detailed information in a shorter amount of time.

"I never thought we would be able to get samples from a baseball hat, or the swabbing of eyeglasses, 15 years ago when I started because we needed a quarter-sized drop of blood in the early 1990s. Now I don`t even need to see a stain," said Beth Ann Marne, supervisor of the DNA laboratory for the Pennsylvania State Police.

Experts who track developments in DNA technology and law enforcement envision policing getting better and faster because of scientific advances.

The world of tomorrow might even contain portable devices to scan DNA right at crime scenes. Someday, if the arguments of civil libertarians can be outmaneuvered, there might be a national DNA database formed from samples taken at birth.

All 50 states maintain DNA databases, and the FBI oversees a national database. States have different requirements for who must submit DNA samples, but University of Wisconsin-Madison law professor Michael Smith said no matter where you look, the trend is for including more information, not less.

However, Smith said, DNA databases are skewing toward including more black men than white men, leading to concerns about racial disparity.

"The databases are building and they`re getting bigger all the time and more comprehensive and more racially distorted," Smith said. "If we want to meet the maximum value for crime control and public safety purposes, we really want to have a near-universal database. We do want to be able to identify people if they leave DNA at a crime scene."

In the United States, California has what the American Civil Liberties Union calls the "most draconian DNA database system in the country" after the recent approval by voters of Proposition 69, which will require in 2009 that people arrested for felonies, but not convicted, submit a DNA sample. The ACLU has filed a class-action suit saying the law is unconstitutional.

In the absence of matching crime-scene DNA with a known felon, a Florida company is doing the next best thing. DNAPrint Genomics is working to create a picture for investigators of what a suspect might look like.

It`s hardly a perfect science. But the company believes it can provide police with a "fuzzy photograph" of a culprit based on a determination of likely ethnicity.

From DNA, the company can tell what percentage of a person`s genetic makeup is likely to be black, white, Asian and American Indian. With those percentages, DNAPrint Genomics can consult a book of "mug shots" submitted by volunteers who have had their own DNA screened.

Depending on what the DNA at a crime scene reveals about a suspect`s genetic makeup, the company can provide a range of pictures of other people with similar genetic profiles, giving investigators a rough idea of the person`s general appearance.

"It`s our feeling that really what we`re doing is placing an eyewitness at the crime scene just by looking at the DNA," said Zach Gaskin, the company`s technical coordinator of forensics. "If a guy is 95 percent Sub-Saharan African, you know you`re not looking for someone who is Caucasian, East Asian or Hispanic."

In the future, DNAPrint Genomics might be able to tell far more about a suspect than ethnicity and eye color. Figuring out how genes dictate, say, the shape of someone`s nose might help immensely to creating what Gaskin called a "genetic sketch."

"In theory, yes, I think it`s possible that we`ll be able to produce a general sketch. And what we`re doing now is producing a fuzzy photo, a driver`s license photo with the picture smudged and no information on it."




___________________________________________________


Mit Langenscheidt übersetzt


Police flinke DNS-Technologie Von JONATHAN DURCH SILBER-Pittsburgh-Nachamtsblatt den 19. Dezember, 2004, begrüßen

- DNS-Technologie - und seine Verwendung in Verbrechenskampf - hat an erstaunlicher Umwandlung in Wiedercentjahren erfahren.

Proben von ein menschlich das genetische Material des Wesens, das einmal für zu klein, zu alt oder auch verunreinigt gehalten wurde, benutzt zu werden in sind ein jetzt für praktisch gehaltener Fall. Sind Große DNS-Datenbanken von Verbrechern sind kompiliert worden und sind regelmäßig von Gesetzesdurchsetzung benutzt worden. Und DNS wird für immer mehr detaillierte Auskunft in einer kürzeren Menge von Zeit gegraben.

"Ich glaubte niemals daß wir einem Baseball Proben abgewinnen könnten hat, oder das Abtupfen von Brillen, 15 Jahre vor als ich startete weil wir einen Viertel-gemessenen Blutstropfen in den frühen 1990er benötigten. Jetzt muß ich einen Fleck nicht einmal sehen", sagte Marne Beth Ann, Pennsylvania-Gruppenleiter des DNS-Labores für den Policestaat.

Fachleute, die Spurentwicklungen in DNS-Technologie und Gesetzesdurchsetzung sich vorstellen, polizeilich zu beaufsichtigen, besser und schneller wegen wissenschaftlicher Fortschritte bekommend.

Die Welt von morgen könnte sogar tragbare Geräte enthalten, um DNS richtig an Verbrechensszenen abzutasten. Someday, wenn die Argumente von bürgerlichen libertarians durch geschicktes Manövrieren überlistet werden können, könnte dort sein ein national DNS-Datenbank, von an der Geburt genommenen Proben gebildet.

Alle 50 Staaten bewahren DNS-Datenbanken, und das FBI überwacht ein national Datenbank. Vereinigte Staaten haben unterschiedliche Anforderungen da wer DNS einreichen muß probiert, aber Universität von Wisconsin-Madison-Gesetzes-Professor Michael Smith sagte nein mildern wo Sie blicken, ist der Trend für einschließlich mehr Auskunft, nicht weniger.

Sagte Schmied allerdings, krümmen DNS-Datenbanken gegen einschließlich mehr schwarzer Männer als weiße Männer, zu Bedenken über rassische Verschiedenheit führend.

"Die Datenbanken bauen auf und sie werden größer alle Zeit und mehr umfassendes und rassischer verzerrtes", sagte Schmied. "Wenn wir dem Maximalwert für Verbrechenskontrolle entsprechen wollen und öffentliche Sicherheit bezweckt, wollen wir wirklich eine in der näheuniversale Datenbank haben. Wir wollen Leute identifizieren können, wenn sie DNS an einer Verbrechensszene verlassen."

In den Vereinigten Staaten hat Kalifornien was der von Amerikaner Civil Liberties Vereinigungsanrufe das "am meisten DNS-Datenbanksystem im Land" Wiedercent nach der Pro-Lagezustimmung von Wählern von 69, von dem Ansprüche in 2009 benötigen daß Leute es für Schwerverbrechen anhielten, aber nicht überführt, reichen eine DNS-Probe ein. Das ACLU hat verfassungswidrig einen Klassenaktions anzugsspruch eingeordnet, der das Gesetz ist.

In Abwesenheit Abstimmungsverbrechensszenen-DNS mit einem bekannten Schwerverbrecher tut eine Florida-Gesellschaft dem nächsten am besten Ding. DNAPrint Genomics arbeitet ein Bild für Untersuchungsbeamte zu schaffen von welchem Verdächtigen könnte blicken mögen.

Es ist kaum eine perfekte Wissenschaft. Aber die Gesellschaft glaubt, daß es Polizei mit einem "fuzzy Foto" eines auf eine Festlegung von wahrscheinlichem ethnicity gestandenen Täters besorgen kann.

Von DNS kann die Gesellschaft sagen, welcher Prozentsatz der genetischen Schminke einer Person wahrscheinlich ist, schwarz, weiß, asiatisch und von Indianer zu sein. Mit jenen Prozentsätzen kann DNAPrint Genomics ein Buch von "Becher-Schüssen" beraten, von Freiwilligen eingereicht, die ihre eigene DNS abgeschirmt haben gelassen haben.

Je nach dem, was die DNS an einer Verbrechensszene über die genetische Schminke eines Verdächtigen enthüllt, schildert Pro-Ordner, von dem die Gesellschaft eine Reihe beschaffen kann, von anderen Leuten mit ähnlichen genetischen, nachgebenden Untersuchungsbeamten eine rauhe Idee der allgemeinen Erscheinung der Person.

Es ist unser Gefühl, daß was wir tun wirklich an Augenzeugen an der Verbrechensszene, gerade indem man die DNS ansieht, stellt, Zach Gaskin sagte, der technische Koordinierer der Gesellschaft von forensics. "Wenn ein Typ 95 Prozent-untersaharan-Afrikaner ist, wissen Sie, daß Sie nicht jemanden suchen, der kaukasisch, ostasiatisch oder Hispanic ist.

In der Zukunft könnte DNAPrint Genomics weit mehr über einen Verdächtigen erzählen können, als ethnicity und Auge färben. Verstehend, wie Gene diktieren, könnte die Form jemandes Nase sagen wir sehr dazu, zu schaffen was Gaskin eine "genetische Skizze nannte, helfen.

" theoretisch, ja glaube ich daß es möglich ist daß wir eine allgemeine Skizze erzeugen können werden. Und was wir jetzt tun erzeugt ein fuzzy Foto, ein Führerschein-Foto mit dem verwischten Bild und keiner Auskunft darüber."

[McFlying]

Pressemitteilung
Seite 1
Für weitere Informationen:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
[e-mail]
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen
29. September 2004
Biofrontera erhält strategisches Investment von DNAPrint in
Höhe von 20 Millionen Euro
Leverkusen, Deutschland − Biofrontera AG gab heute bekannt, dass auf
der Basis eines strategischen Investments von DNAPrint™ genomics, Inc.,
Sarasota, FL, USA eine Joint Venture Rahmenvereinbarung zwischen
beiden Unternehmen geschlossen wurde. DNAPrint erwirbt von Biofrontera
neu ausgegebene Vorzugsaktien der Serie B für 20 Mio Euro. Heidelberg
Innovation, 3i Group, TechnoMedia Kapitalbeteiligungsgesellschaft Köln
mbH sowie Herr Prof. Dr. Riesner erhöhen das Gesamtinvestitionsvolumen
auf 21,2 Mio Euro.
Biofrontera wird das aufgenommene Kapital zur Weiterentwicklung der
klinischen und präklinischen Produktpipeline nutzen. DNAPrint werden zwei
der sechs Aufsichtsratssitze der Biofrontera zugesprochen, und Prof. Dr.
Hermann Lübbert, Vorstandsvorsitzender der Biofrontera AG, wird dem
Board von DNAPrint beitreten.
Durch die unterzeichnete Rahmenvereinbarung sollen beide
Technologieplattformen zum gegenseitigem Nutzen der Unternehmen
kombiniert werden. Biofronteras Forschungs- und Entwicklungsprojekte für
neue Arzneimittel sollen durch DNAPrints einzigartigen Ansatz zur
Entwicklung von Diagnostika ergänzt werden, der auf
populationsgenetischen Analysen beruht. Patientengruppen können
hierdurch besser ausgewählt werden, damit Wirksamkeit und
Nebenwirkungen von potenziellen Medikamenten leichter nachweisbar
werden. Das Management erwartet, dass die frühzeitige Einbindung
geeigneter diagnostischer Tests den Prozess der Arzneimittelentwicklung
vereinfachen und beschleunigen wird.
Das Investment von DNAPrint ist gesichert durch die Zusage des Dutchess
Private Equity Fonds, der auf Anforderung von DNAPrint neu ausgegebene
DNAPrint Aktien für bis zu 35 Mio US$ innerhalb der kommenden beiden
Jahre erwerben wird. Die Transaktion wird mit der Registrierung der
neugeschaffenen Aktien am Aktienmarkt wirksam.
Pressemitteilung
Seite 2
„Der Abschluss einer derartigen Partnerschaft mit einem US Unternehmen
ist ein bedeutender Meilenstein für unser Unternehmen. Die
eingeworbenen Kapitalressourcen ermöglichen es uns unsere
Produktkandidaten in der klinischen Entwicklung voranzutreiben und
hierdurch den Wert der Firma drastisch zu steigern,“ kommentierte Prof.
Hermann Lübbert. „Mit Hilfe des Investments wollen wir unser führendes
Produkt BF-Derm1 zur Behandlung von chronischer Urtikaria und weitere
Produktkandidaten in den nächsten drei Jahren zur Marktreife führen.
Durch den Einsatz der DNAPrint Technologie wird die Entwicklung unserer
Arzneimittel beschleunigt und weniger kostenintensiv. Die Möglichkeit, die
Wirkung eines Medikaments in einem bestimmten Patienten vorherzusagen
wird zur optimalen Versorgung der Patienten beitragen. Schnellere
Entwicklungserfolge werden die Biofrontera einem angestrebten
Börsengang näher bringen.“
Richard Garbriel, Vorstandsvorsitzender und Präsident von DNAPrint
genomics Inc, sagte: „Wir freuen uns, dass wir der erfolgsversprechenden
Verbindung zwischen Biofrontera und DNAPrint eine zuverlässige
Kapitalbasis bieten können. Wir sind überzeugt, dass diese Finanzierung
nach der Registrierung der Aktien durch die SEC unseren Aktionären eine
Wertsteigerung bringt, die deutlich über den eigentlichen Wert der
Biofrontera Aktien hinausgeht. Durch die Kombination der
Technologieplattformen hoffen wir die derzeitigen Umsatzchancen beider
Unternehmen zu verbessern und dem Markt Lösungen für viele Probleme
der Pharmaforschung und -entwicklung anzubieten.“
Biofrontera AG
Biofrontera’s strategisches Ziel ist der Aufbau eines Specialty-
Pharmaunternehmens im Bereich Dermatologie bei Nutzung interner
Forschungskapazitäten zur Erweiterung der bestehenden Produktpipeline.
www.biofrontera.com
DNAPrint genomics Inc.
DNAPrint genomics Inc. nutzt patentierte DNA-basierende Forschungsmethoden
um daraus ihre Produkte und Services zu entwickeln. Die Firma hat 2003 die
Produkte ANCESTRYbyDNA™ in den Verbrauchermarkt und DNAWitness™ in
den forensischen Markt eingeführt und entwickelt derzeit Produkte im
Pharmacogenomics-Markt. Die Firma ist am NASDAQ OTC Bulletin Board (DNAP)
und der Berliner Börse (WKN-Nummer 940906) gelistet.
www.dnaprint.com

[tonimontana]

hi leute ,
kann einer den aktuellen kurs von 19.30Uhr ermitteln.
hier im board steht nur was von 18.00Uhr.
mfg toni